Citi lowered the firm’s price target on MacroGenics to $14 from $16 and keeps a Buy rating on the shares. The analyst updated biotechnology models to reflect the Q2 reports.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGNX:
- MacroGenics management to meet virtually with B. Riley
- MacroGenics price target lowered to $5 from $8 at BMO Capital
- MacroGenics sees cash plus milestones to support cash runway into 2026
- MacroGenics reports Q2 EPS (89c), consensus (59c)
- MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results